Founders Capital Management (Texas)’s Karyopharm Therapeutics KPTI Stock Holding History

Founders Capital Management (Texas)’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-133	Closed	-$1.66K	–	380
2024 Q3	$1.66K	Hold	133	–	–	﹤0.01%	337
2024 Q2	$1.74K	Hold	133	–	–	﹤0.01%	333
2024 Q1	$3.02K	Hold	133	–	–	﹤0.01%	325
2023 Q4	$1.73K	Hold	133	–	–	﹤0.01%	354
2023 Q3	$2.68K	Hold	133	–	–	﹤0.01%	362
2023 Q2	$3.58K	Hold	133	–	–	﹤0.01%	351
2023 Q1	$8K	Hold	133	–	–	0.01%	326
2022 Q4	$7K	Hold	133	–	–	0.01%	322
2022 Q3	$11K	Hold	133	–	–	0.01%	284
2022 Q2	$9K	Sell	133 -67	-34%	-$6.14K	0.01%	321
2022 Q1	$19K	Hold	200	–	–	0.01%	217
2021 Q4	$19K	Hold	200	–	–	0.01%	217
2021 Q3	$17K	Buy	200 +133	+199%	+$13.8K	0.01%	230
2021 Q2	$10K	Buy	+67	New	+$9.72K	0.01%	265

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Founders Capital Management (Texas)'s KPTI Position: Q4 2024 in Review

Founders Capital Management (Texas) sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 133 shares — an estimated $1.66K sold.

Founders Capital Management (Texas) first reported a position in KPTI in Q2 2021 and held it in 14 quarters. The position peaked at $19K in Q1 2022. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

Founders Capital Management (Texas) reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
Founders Capital Management (Texas) sold 133 Karyopharm Therapeutics shares in Q4 2024, an estimated $1.66K.
Founders Capital Management (Texas) first reported a position in Karyopharm Therapeutics in Q2 2021 and held it in 14 quarters.
Founders Capital Management (Texas)'s Karyopharm Therapeutics position peaked at $19K in Q1 2022.
87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Founders Capital Management (Texas)'s 13F filing for Q4 2024, filed 13 Jan 2025.